Investment Analysts’ Weekly Ratings Changes for Corcept Therapeutics (CORT)

Several analysts have recently updated their ratings and price targets for Corcept Therapeutics (NASDAQ: CORT):

• 1/2/2026 – Corcept Therapeutics had its price target lowered by analysts at HC Wainwright from $145.00 to $90.00. They now have a “buy” rating on the stock.
• 1/2/2026 – Corcept Therapeutics had its price target lowered by analysts at Canaccord Genuity Group Inc. from $140.00 to $99.00. They now have a “buy” rating on the stock.
• 12/31/2025 – Corcept Therapeutics was given a new $50.00 price target on by analysts at Truist Financial Corporation.
• 12/31/2025 – Corcept Therapeutics was downgraded by analysts at Wolfe Research from a “peer perform” rating to an “underperform” rating. They now have a $30.00 price target on the stock.
• 12/29/2025 – Corcept Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Corcept Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – Corcept Therapeutics is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $95.00 price target on the stock.
• 12/16/2025 – Corcept Therapeutics is now covered by analysts at UBS Group AG. They set a “hold” rating and a $95.00 price target on the stock.
• 12/15/2025 – Corcept Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Corcept Therapeutics was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
• 12/8/2025 – Corcept Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Corcept Therapeutics had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Corcept Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
• 11/19/2025 – Corcept Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Corcept Therapeutics is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
• 11/13/2025 – Corcept Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the sale, the insider directly owned 1,235 shares of the company’s stock, valued at $43,447.30. The trade was a 94.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $73.65, for a total value of $368,250.00. Following the completion of the sale, the insider directly owned 10,277 shares of the company’s stock, valued at approximately $756,901.05. This trade represents a 32.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 194,500 shares of company stock valued at $14,186,410. 20.80% of the stock is currently owned by corporate insiders.

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.